Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 1501 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 1502 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 70 |
| 1503 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 75 |
| 1504 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 56 |
| 1505 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 23 |
| 1506 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 54 |
| 1507 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 1508 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 70 |
| 1509 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 1510 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 48 |
| 1511 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 72 |
| 1512 | Bone Marrow Family | Allogeneic | Chronic Lymphocytic Leukemia Richter Transformation | Hematology | 2024 | Standard Therapy | Poland | 55 |
| 1513 | Bone Marrow Family | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 63 |
| 1514 | Bone Marrow Family | Allogeneic | Follicular Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 48 |
| 1515 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 1516 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 58 |
| 1517 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 70 |
| 1518 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome – Refractory Cytopenia Of Childhood | Hematology | 2024 | Standard Therapy | Poland | 14 |
| 1519 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome/ Myeloproliferative Neoplasms | Hematology | 2024 | Standard Therapy | Germany | 61 |
| 1520 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome-MPN | Hematology | 2024 | Standard Therapy | Poland | 71 |
| 1521 | Bone Marrow Family | Allogeneic | Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 68 |
| 1522 | Bone Marrow Family | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 64 |
| 1523 | Bone Marrow Family | Allogeneic | Polycythemia Vera/Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 74 |
| 1524 | Bone Marrow Family | Allogeneic | Primary Myelofibrosis | Hematology | 2024 | Standard Therapy | Germany | 62 |
| 1525 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 68 |
| 1526 | Bone Marrow Family | Allogeneic | Myelodysplasia | Hematology | 2024 | Standard Therapy | United Kingdom | 57 |
| 1527 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 69 |
| 1528 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 58 |
| 1529 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 60 |
| 1530 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 71 |
| 1531 | Bone Marrow Family | Allogeneic | High risk Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 69 |
| 1532 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 74 |
| 1533 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 15 |
| 1534 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 8 |
| 1535 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 12 |
| 1536 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 8 |
| 1537 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 52 |
| 1538 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 57 |
| 1539 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 66 |
| 1540 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 5 |
| 1541 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 54 |
| 1542 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 56 |
| 1543 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 3 |
| 1544 | Bone Marrow | Allogeneic | Adrenoleukodystrophy | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1545 | Bone Marrow | Allogeneic | Adrenoleukodystrophy | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1546 | Bone Marrow | Allogeneic | Adrenoleukodystrophy | Hematology | 2024 | Standard Therapy | Poland | 9 |
| 1547 | Bone Marrow | Allogeneic | B-Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1548 | Bone Marrow | Allogeneic | Chronic Granulomatous Disease | Hematology | 2024 | Standard Therapy | Poland | 4 |
| 1549 | Bone Marrow | Allogeneic | Chronic Granulomatous Disease | Hematology | 2024 | Standard Therapy | Poland | 41 |
| 1550 | Bone Marrow | Allogeneic | Chronic Lymphocytic Leukemia Richter Transformation | Hematology | 2024 | Standard Therapy | Poland | 55 |
| 1551 | Bone Marrow | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 1552 | Bone Marrow | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 12 |
| 1553 | Bone Marrow | Allogeneic | Diffuse Large B-Cell Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 61 |
| 1554 | Bone Marrow | Allogeneic | Genetically Determined Thrombocytopenia | Hematology | 2024 | Standard Therapy | Poland | 4 |
| 1555 | Bone Marrow | Allogeneic | High Risk Acute Myeloid Leukaemia | Hematology | 2024 | Standard Therapy | Poland | 13 |
| 1556 | Bone Marrow | Allogeneic | Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 32 |
| 1557 | Bone Marrow | Allogeneic | Inherited Metabolic Disease | Hematology | 2024 | Standard Therapy | Poland | 11 |
| 1558 | Bone Marrow | Allogeneic | Mds-Rcc Relapse | Hematology | 2024 | Standard Therapy | Poland | 14 |
| 1559 | Bone Marrow | Allogeneic | Mixed Cellularity Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 43 |
| 1560 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 14 |
| 1561 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 8 |
| 1562 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 14 |
| 1563 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 1564 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 9 |
| 1565 | Bone Marrow | Allogeneic | Osteopetrosis type B | Hematology | 2024 | Standard Therapy | Poland | 13 |
| 1566 | Bone Marrow | Allogeneic | Other Leukemia | Hematology | 2024 | Standard Therapy | Poland | 9 |
| 1567 | Bone Marrow | Allogeneic | Primary Immunodeficiency | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1568 | Bone Marrow | Allogeneic | Primary Immunodeficiency Xlp-1 | Hematology | 2024 | Standard Therapy | Poland | 18 |
| 1569 | Bone Marrow | Allogeneic | Relapse T-Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 12 |
| 1570 | Bone Marrow | Allogeneic | Secondary Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 4 |
| 1571 | Bone Marrow | Allogeneic | Secondary Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 15 |
| 1572 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1573 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 3 |
| 1574 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 10 |
| 1575 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 21 |
| 1576 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 18 |
| 1577 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 49 |
| 1578 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 16 |
| 1579 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 24 |
| 1580 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 13 |
| 1581 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 14 |
| 1582 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 21 |
| 1583 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1584 | Bone Marrow | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2024 | Standard Therapy | Poland | 2 |
| 1585 | Bone Marrow | Allogeneic | Severe Congenital Neutropenia | Hematology | 2024 | Standard Therapy | Poland | 1 |
| 1586 | Bone Marrow | Allogeneic | Shwachman-Diamond Syndrome | Hematology | 2024 | Standard Therapy | Poland | 10 |
| 1587 | Bone Marrow | Allogeneic | Sickle Cell Disease | Hematology | 2024 | Standard Therapy | Poland | 9 |
| 1588 | Bone Marrow | Allogeneic | Biphenotypic Acute Leukemia | Hematology | 2024 | Standard Therapy | Ukraine | 10 |
| 1589 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 58 |
| 1590 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | United Kingdom | 12 |
| 1591 | Bone Marrow | Allogeneic | hemophagocytic lymphohistiocytosis | Hematology | 2024 | Standard Therapy | Sweden | 4 |
| 1592 | Bone Marrow | Allogeneic | Severe combined immunodeficiency | Hematology | 2024 | Standard Therapy | Germany | 1 |
| 1593 | Bone Marrow | Allogeneic | Beta-Thalassemia Major | Hematology | 2024 | Standard Therapy | India | 11 |
| 1594 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Austria | 4 |
| 1595 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Norway | 33 |
| 1596 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Spain | 16 |
| 1597 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Switzerland | 5 |
| 1598 | Bone Marrow | Allogeneic | T- Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Ireland | 6 |
| 1599 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 12 |
| 1600 | Bone Marrow | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2024 | Standard Therapy | USA | 4 |